Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold shares of common stock on October 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., engaged in transactions involving the company's stock.
• Guggenhime exercised stock options to acquire 42,000 shares of common stock at a price of $5.35 per share.
• Concurrently, Guggenhime sold 42,000 shares of common stock at weighted average prices of $115.263 and $116.191, resulting in the sale of 36,114 shares and 5,886 shares respectively.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on May 17, 2024.
• Following these transactions, Guggenhime directly owns 90,383 shares of Vaxcyte common stock.
• He also holds options to purchase 278,827 shares of Vaxcyte common stock.

Sentiment

Score: 5

Explanation: This is a routine filing related to insider trading under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. The use of a 10b5-1 plan suggests that these transactions were pre-planned and not based on any material non-public information.

Comparison to Industry Standards

• Monitoring insider transactions is a common practice in the biotech industry.
• Companies like Moderna and BioNTech also have executives who regularly trade shares, often under 10b5-1 plans.
• The size and frequency of these transactions are typical for executives at publicly traded biotech firms.

Stakeholder Impact

• Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.
• However, transactions under a 10b5-1 plan are less indicative of current sentiment.

Key Dates